Co-expression of SLC7A5/SLC3A2 mRNA within the METABRIC cohort was used to determine the prognostic value in ER+/HER2− breast cancer, whereby the SLC7A5+SLC3A2+ subgroup was associated with poor clinical outcome. This evidence concerns the gene SLC3A2 and breast carcinoma.